Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers formulations in various therapeutic areas, including central nervous system, dermatology, cardiology, oncology, neuropsychiatry, gastroenterology, anti-infectives, diabetology, pain/analgesics, vitamins/minerals/nutrients, respiratory, gynaecology, urology, ophthalmology, orthopaedic, nephrology, dental, and other areas. It provides APIs for anti-cancers, peptides, steroids, hormones, and immunosuppressant drugs. In addition, the company offers generic medications, such as tablets, capsules, injectables, inhalers, ointments, creams, and liquids; speciality medications, and antiretrovirals medications, as well as over-the-counter products. The company was founded in 1983 and is headquartered in Mumbai, India.

Revenue projections:

Revenue projections for SUNPHARMA
Revenue projections for SUNPHARMA

SUNPHARMA's revenue projections indicate a decrease from last year's performance, which could lead to investor caution. A fall in revenue is likely to negatively impact the company's profitability, causing concern for shareholders who may view this as a signal of declining financial health.

Financial Ratios:

currentRatio 2.892000
forwardPE 27.835083
debtToEquity 3.259000
earningsGrowth -0.188000
revenueGrowth 0.081000
grossMargins 0.795590
operatingMargins 0.213060
trailingEps 45.620000
forwardEps 32.680000

With a current ratio of 2.892, SUNPHARMA has the liquidity needed to easily service its short-term debt. The company's cash reserves and current assets are sufficient, indicating that SUNPHARMA is in a strong position to meet its immediate financial obligations without difficulty.
SUNPHARMA's Forward PE is in a reasonable range, indicating the stock is priced well relative to its earnings. The stock isn't overpriced, which leaves room for future growth, making it an attractive option for investors seeking value and long-term gains.
SUNPHARMA's low growth in both earnings and revenue indicates a likely decrease in profits. This suggests the company may be facing financial challenges, and investors should be cautious about its future performance.
Sun Pharmaceutical Industries Limited's positive gross and operating margins suggest strong profitability. These margins reflect effective cost management and revenue generation, indicating that the company is efficiently managing its operations and maintaining financial health.
Sun Pharmaceutical Industries Limited's forward EPS being lower than its trailing EPS suggests the company is expected to see reduced profitability in the current financial year compared to the previous one. This signals a potential decline in earnings, raising concerns about future financial performance.

Price projections:

Price projections for SUNPHARMA
Price projections for SUNPHARMA

SUNPHARMA's price projections have gradually declined, indicating growing uncertainty about the company's ability to meet previous targets. The downward trend reflects a more conservative view of SUNPHARMA's future.

Recommendation changes over time:

Recommendations trend for SUNPHARMA
Recommendations trend for SUNPHARMA


The recent buy bias from analysts suggests SUNPHARMA is seen as a strong investment, encouraging more investors to consider it. With this favorable sentiment, SUNPHARMA appears to be a reliable option for parking money, offering stability and long-term growth potential in the stock market.